Adverse reactions and antibody responses to acellular pertussis vaccine.
Two types of acellular pertussis vaccine are used in Japan: the filamentous hemagglutinin (F-HA) predominant type and the pertussis toxin (PT)-F-HA type. We tested one lot of vaccine from each of three manufacturers (lots A and B, F-HA predominant type; lot C, PT-F-HA type). One hundred fifteen healthy children between the ages of 3 months and 23 months were immunized with one of the three lots of acellular pertussis vaccine to assess adverse reactions and antibody responses. The incidence of fever (temperature greater than or equal to 38 degrees C) was 2.6% for lot A, 1.2% for lot B, and 2.5% for lot C. The incidence of local reactions greater than 5 cm in diameter was 1.9% for lot A, 2.4% for lot B, and 3.3% for lot C. Thus no significant differences in adverse reaction were observed. The anti-PT antibody responses in the tested vaccines were equal to or greater than those in patients with pertussis in the convalescent stage, and the anti-F-HA antibody responses were far higher than those of convalescing patients. Lot C produced the highest anti-PT antibody, and Lot A the highest anti-F-HA antibody.
D000373:Agglutinins / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D004306:Dose-Response Relationship, Immunologic; D005334:Fever / Q000209:etiology; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects; D007223:Infant; D051379:Mice; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014917:Whooping Cough / Q000276:immunology
D000373:Agglutinins; D000914:Antibodies, Viral; D010567:Pertussis Vaccine